A clinical hold is an order FDA issues under 21 CFR 312.42 to delay a proposed study or suspend one already underway. Most sponsors know that much. Fewer know that the 30-day period everyone quotes back at them is not a deadline they are racing against — it is FDA's own clock, and it does not start on the day the response is filed. It starts once FDA's review division has confirmed the response is actually complete, a determination the agency is supposed to make within 14 days.

Full hold vs. partial hold

The distinction is not cosmetic. A full clinical hold suspends every piece of clinical work requested under the IND: no new subjects, and subjects already enrolled come off the investigational drug unless FDA specifically permits continuation for safety reasons. A partial clinical hold reaches only what the order names — a single protocol among several, part of a protocol, or one site in a multi-site study — and everything outside that scope proceeds under the same IND application without interruption. Sponsors who read a partial hold as if it were full end up pausing work FDA never asked them to pause, which costs time the hold itself did not require.

14 days
The window FDA's review division has to tell you a response isn't complete — before the 30-day clock even starts.
30 days
FDA's own clock to respond in writing to a complete response, under §312.42(e). Not the sponsor's deadline — the agency's.
§312.42(b)(2)(ii)
The design-deficiency ground available for Phase 2/3 holds, with no equivalent among the Phase 1 grounds.

What actually starts the clock

The common mistake is treating the 30 days as symmetric — as if the sponsor also has 30 days to respond, so a response filed at day 29 is somehow on time. There is no such deadline. A sponsor can take as long as the science requires. What matters is what happens after filing: if the review division decides the response does not address every issue in the hold order, it is not a complete response, and FDA's 30-day review clock never starts. A rushed, partial response filed early can cost more time than a complete one filed later, because an incomplete filing resets nothing except the sponsor's confidence that the clock is running.

  • Phase 1 grounds (§312.42(b)(1)). Unreasonable and significant risk to subjects; unqualified investigators; a misleading or materially incomplete investigator's brochure; or an IND that lacks the information required under §312.23 to assess risk.
  • Added ground for Phase 2/3 (§312.42(b)(2)(ii)). A protocol "clearly deficient in design to meet its stated objectives" — a scientific-merit ground with no Phase 1 counterpart, because early-phase protocols are not held to the same design bar.
  • Before the order issues. FDA is required to attempt to discuss and resolve the matter with the sponsor first (§312.42(c)) — the conversation that precedes a hold is often the clearer signal, not the letter that follows it.
  • If imposed verbally. A written explanation of the basis for the hold follows within 30 days (§312.42(d)); the clock in this article is the separate one governing FDA's review of the sponsor's response.
Filing early against an assumed deadline does not make the clock start sooner. Filing complete does. Why the 14-day completeness gate is the real deadline

When the response alone won't move it

Some holds resolve cleanly on paper: FDA names the deficiency, the sponsor supplies the missing data or analysis, and the hold lifts within the 30-day window. Others don't, because the disagreement is scientific rather than administrative — FDA and the sponsor read the same data differently. That is what Type A meetings exist for: FDA aims to respond to a Type A request within 14 days and hold the meeting within 30, specifically for programs stalled by a clinical hold, a disputed Special Protocol Assessment, or a comparable dispute. Requesting one is not an admission that the written response failed — it is often the faster path when the underlying question is one a letter cannot settle.

A clinical hold response sequence that holds up
  1. Map the order to its actual scope. Confirm full vs. partial against §312.42 before pausing anything the order didn't reach.
  2. Answer every named issue. A response that resolves three of four cited deficiencies is not complete, and the 30-day clock will not start on it.
  3. Request a Type A meeting where the issue is scientific. A documented FDA position beats a second guess at what the agency wants.
  4. Track FDA's clock, not an assumed one. It starts at completeness confirmation, not at filing — plan the program timeline around that trigger.

None of this changes what caused the hold. It changes how much time gets spent finding out that a response wasn't complete, or that a hold everyone treated as full was actually partial. Sponsors who build the response against the regulation's actual sequence — the pre-order discussion, the completeness gate, FDA's own 30-day clock — get through a hold in the time the hold actually requires. Sponsors who build it against an assumed sponsor-side deadline tend to spend part of that time discovering the deadline was never theirs. If you are inside an active hold and the path forward is unclear, that is precisely where our IND strategy work starts.

Frequently asked questions

What is the difference between a full and a partial clinical hold?

A full clinical hold suspends all clinical work under an IND. A partial clinical hold suspends only the named piece — one protocol, part of a protocol, or a specific site in a multi-site study — and everything outside that scope may continue. Under 21 CFR 312.42, both are orders FDA issues to the sponsor; neither lifts until FDA says so in writing.

How long does a sponsor have to respond to a clinical hold?

There is no regulatory deadline for the sponsor to respond. The 30-calendar-day clock in 21 CFR 312.42 belongs to FDA: once the sponsor submits a complete response, FDA has 30 days to review it and respond in writing. The response only starts that clock once FDA's review division has confirmed, in principle within 14 days, that it actually addresses every issue in the hold order.

What makes a clinical hold response "complete"?

A complete response addresses every issue identified in the clinical hold order, item by item, with the data or analysis FDA asked for — not a partial fix or a promise to follow up. If the review division decides a submission does not meet that bar, it is not treated as a complete response and the 30-day review clock does not start.

Sources & further reading

  1. eCFR. 21 CFR 312.42 — Clinical holds and requests for modification. ecfr.gov
  2. FDA. Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products — Guidance for Industry. fda.gov
  3. FDA. Submitting and Reviewing Complete Responses to Clinical Holds — Guidance for Industry. fda.gov

This article is provided for general informational purposes and reflects the regulatory landscape as of September 2026. It is not legal or regulatory advice. Confirm current clinical hold procedures and timelines with FDA or qualified counsel before acting.